Abstract The rs3834129 polymorphism, in the promoter of CASP8 gene, has been recently reported as associated with breast cancer risk in the general population, with the minor allele del having a protective effect. Some of the genetic variants found associated with breast cancer risk were reported as risk modifiers in individuals with mutations in BRCA1 and BRCA2 genes. Here, we tested the effect of the rs3834129 del allele on breast cancer risk in BRCA mutation carriers. The rs3834129 was genotyped in a total of 1,207 Italian female BRCA mutation carriers. Of these, 740 carried a BRCA1 mutation and 467 a BRCA2 mutation. Overall, 699 were affected with breast cancer and 508 were unaffected. When considering class 1 (lossof-function) BRCA mutations, hazard ratios estimated by weighted multivariable Cox regression model, for individuals with at least one copy of the del allele, were 1.46 (95% confidence interval (CI): 1.08-1.99) for BRCA1 and BRCA2 mutation carriers combined, 1.74 (95% CI: 1.24-2.46) for BRCA1 mutation carriers, and 1.09 (95% CI: 0.66-1.80) for BRCA2 mutation carriers. These results suggest that the minor allele del of rs3834129 is associated under a dominant model with increased breast cancer risk in carriers of BRCA1 mutations but not in carriers of BRCA2 mutations.
Introduction
Caspases are apical positive mediators of apoptosis. Apoptosis is a key process in maintaining cell proliferation and controlling cancer development. For this reason, germline variations of caspase encoding genes have been studied with respect to cancer risk. The common polymorphism rs3834129, consisting of a six-nucleotide (AGTAAG) insertion/deletion in the promoter of the CASP8 gene at nucleotides -657 to -652, has been recently investigated in association with breast cancer risk. The first study, carried out in unselected Chinese breast cancer cases, suggested that the minor allele del (also referred to as -652 6N del) is protective versus breast cancer, with an odds ratio (OR) of heterozygotes 0.65 (95% confidence interval, CI: 0.54-0.78) and the OR of homozygotes for the del allele 0.50 (95% CI: 0.34-0.74) [1] . These findings, however, were not confirmed in each of three subsequent studies in Caucasian unselected breast cancer cases and controls [2] [3] [4] . We performed a fourth study in Italian familial breast cancer cases with no mutations in BRCA genes. This study indicated a lack of association between rs3834129 and breast cancer risk, but a case-only analysis showed a significant increasing trend for the del/del genotype frequency with later age of breast cancer diagnosis [5] . More recently, two concomitant meta-analyses corroborated the protective effect of the del allele versus breast cancer risk. The first was based on the four abovementioned studies and estimated for the del allele carriers an overall OR of 0.94 of borderline significance (95% CI: 0.884-1.008). This analysis pointed out that each of the single studies was probably statistically underpowered to detect the protective effect [6] . The second meta-analysis combined three different case-control series, and the ORs for the heterozygous and for the homozygotes for the del allele were 0.95 (95% CI: 083-1.08) and 0.82 (95% CI: 070-0.95), respectively [7] . Thus, it appears that in the general population the rs3834129 polymorphism is associated with breast cancer risk and that the minor allele del is acting as a protective factor.
It has been shown that most of the genetic variants associated with breast cancer risk identified in the general population by genome-wide association studies are also modifiers of breast cancer risk in carriers of mutations in BRCA1 or BRCA2 genes [8, 9] . In the present study, we investigated if the rs3834129 polymorphism modifies breast cancer risk testing a large series of Italian female carriers of mutations in BRCA genes.
Materials and methods

Study populations
BRCA gene mutation carriers were originally recruited at eight different cancer genetic clinics participating in the Consorzio degli Studi Italiani sul Tumore Ereditario alla Mammella (CONSIT TEAM; Consortium of Italian Studies on Hereditary Breast Cancer). The CONSIT TEAM was established in 2009 as a national initiative to identify and study genetic modifiers of breast cancer risk and as a collaborative group to studies promoted by the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) [10] . Eligibility criteria for the CONSIT TEAM were those adopted by CIMBA. All individuals included in this study were female carriers of a mutation in either BRCA1 or BRCA2, classified as a deleterious according to widely recognized criteria (Breast Cancer Information Core, http://research.nhgri.nih.gov/bic/). All individuals were enrolled at host institutions under research or clinical protocols approved by the local Ethic Committees and were C18 years old at recruitment. Clinical information collected included data of birth, BRCA mutation description and type (according to functional effect), age at last follow-up, age at breast or ovarian cancer diagnosis, and age at bilateral prophylactic mastectomy. Related individuals were identified by a unique family identifier.
Genotyping
Genotyping of rs3834129 was performed at Consortium for Genomic Technologies (Cogentech), Milan by direct sequencing (primer sequences and PCR protocol are available upon request). Deviation from Hardy-Weinberg equilibrium (HWE) was evaluated as a quality-control check in single individuals randomly selected from each family using Pearson chi-squared test.
Statistical analysis
The association of rs3834129 with breast cancer risk was assessed by estimating hazard ratios (HRs) and their corresponding 95% CI using weighted multivariable Cox proportional hazards regression with robust estimates of variance, by clustering the observations on the family identity number. This approach allowed correcting for the bias in HR and variance estimates related to the fact that BRCA1 and BRCA2 mutation carriers are not randomly sampled with respect to their disease status and that they could belong to the same family. A detailed description of this approach has been published elsewhere [11, 12] . Individuals were classified according to their age at the first of the following events: breast cancer diagnosis, ovarian cancer diagnosis, bilateral prophylactic mastectomy or last observation. Only individuals censored at breast cancer diagnosis were considered affected, while the other were considered unaffected. Weights were assigned separately for BRCA1 and BRCA2 mutation carriers according to their disease status and by age interval (\25, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, [70 years), such that the weighted observed incidences in the sample agree with established estimates for mutation carriers [13] .
We considered log-additive, dominant and ''three genotypes'' models. Additional covariates included in each model were: center at which BRCA mutation carriers were ascertained and year of birth, as previously reported (11). The latter, grouped in five classes (\1940, 1940-1949, 1950-1959, 1960-1969, C1970) , was included to account for possible cohort effect. We evaluated the goodness of fit of the data to the different models by using the Akaike's information criterion (AIC) [14] . All statistical analyses were performed with the SAS software (Version 9.2.; SAS Institute Inc. Cary, NC).
Results
Overall 1,241 BRCA1 and BRCA2 mutation carriers were contributed by the collaborating centers (Table 1) . Genotyping failed for 18 samples. Thirteen women who selfreported as ''non-Caucasian'' and three women who carried mutations in both BRCA1 and BRCA2 were excluded from the study. Thus, 1,207 individuals remained included. Of these, 740 carried a BRCA1 mutation and 467 a BRCA2 mutation. These individuals were censored at the age of the first of the following events: breast cancer diagnosis (n = 699), last observation (n = 318), ovarian cancer diagnosis (n = 173), and bilateral prophylactic mastectomy (n = 17).
Genotypic frequencies of rs3834129 and weighted multivariable Cox model results are shown in Table 2 . The genotypic frequencies were consistent with HWE. There was evidence for association with breast cancer risk for BRCA1 mutation carriers but not for BRCA2 mutation carriers. Each copy of the minor allele del conferred an HR of 1.23 (95% CI: 1.02-1.49) and of 0.92 (95% CI: 0.66-1.29) in the two groups, respectively. However, by resorting to a ''three genotypes'' model, the estimated risk for heterozygotes was higher than the estimated risk for homozygotes for the risk allele del, suggesting that its effect was not consistent with a log-additive model. Using the AIC as overall measure of the goodness of fit of the data to different models, the dominant model was selected. Under this parsimonious model, the HR for carriers with at least one copy of the del allele was 1.52 (95% CI: 1.14-2.02) for BRCA1 mutation carriers, and 1.35 (95% CI: 1.04-1.76) for BRCA1 and BRCA2 mutation carriers combined.
We pursued with an additional analysis and classified BRCA mutation according to their expected functional effects. Mutations of class 1 were those potentially causing loss-of-function and thus haplo-insufficiency; mutations of class 2 those potentially causing stable mutant protein with possible dominant negative effect [9] . Mutations were classified as of class 1 or class 2 as indicated in the database available to CIMBA collaborating groups at the CIMBA web site (http://www.srl.cam.ac.uk/consortia/cimba/ members/login.html). Carriers of class 1 mutations were Table 3 . The number of class 2 mutation carriers was too small to justify separate analysis. Again, the dominant model resulted the most appropriate, and HR individuals with at least one copy of the del allele was 1.74 (95% CI: 1.24-2.46) for BRCA1 mutation carriers, and 1.46 (95% CI: 1.08-1.99) for BRCA1 and BRCA2 mutation carriers combined.
Discussion
Our study showed that the del allele of the rs3834129 polymorphism increases breast cancer risk in BRCA1 HR hazard ratio (adjusted for center and year of birth), CI confidence interval, nor/nor common homozygotes, nor/del heterozygotes, del/del rare homozygotes [16] . This indicates that genetic factors can be differentially associated with the risk for specific breast cancer subtypes. Consistently, a few single nucleotide polymorphisms (SNPs) identified in the general population as breast cancer low-penetrance alleles have been shown to increase breast cancer risk in BRCA2, but not BRCA1 mutation carriers [8, 9] . To our knowledge, this is the first report of a breast cancer associated allele with opposite effect in the general population compared to BRCA1 mutation carriers. Further analyses are necessary to confirm the association of the rs3834129 del allele with breast cancer ER status and to verify if this association, that we observed in Italian at risk women, is present also in other populations. It has been shown that the del allele destroys a binding element in the CASP8 promoter for the stimulatory protein 1 (Sp1) and causes a reduced expression of the caspase-8 protein that decreases apoptosis of antitumor T lymphocytes [1] . Consequently, it was postulated that this could affect antitumor immune response and ultimately decrease cancer susceptibility. On the other hand, BRCA1-associated breast cancers show an increased proliferation activity, as measured by mitotic count, significantly higher than that observed in sporadic cancers and in cancers from BRCA2 mutation carriers [17] . Thus, it might be speculated that in individuals who are particularly prone to develop highly replicating tumors a reduced apoptosis response leads to a less efficient mechanism of control of cancer progression and to increased risk.
In conclusion, our study suggested that rs3834129 is a risk modifier in BRCA1 mutation carriers. In particular, the del allele is associated with an increased breast cancer risk under a dominant model. Moreover, the risk increase appeared to be higher in carrier of mutations causing haplo-insufficiency.
